tbuckley/cabot-search huggingface dataset:
Association of Ticagrelor vs Clopidogrel With Major Adverse Coronary Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
Authors: Ricky D. Turgeon, Sheri L. Koshman, Erik Youngson, Bryan Har, Stephen B. Wilton, Matthew T. James, Michelle M. Graham
Journal: JAMA Internal Medicine (2020)

<h3>Importance</h3> Guidelines currently recommend ticagrelor over clopidogrel for patients with acute coronary syndrome (ACS) based on randomized clinical trial data in which ticagrelor reduced major adverse coronary events (MACE) vs clopidogrel but increased bleeding and dyspnea. <h3>Objective</h3> To compare the risk of MACE with ticagrelor vs clopidogrel in patients with ACS treated with percutaneous coronary intervention (PCI), to compare major bleeding and dyspnea, and to evaluate the association between P2Y<sub>12</sub>inhibitor adherence and MACE. <h3>Design, Setting, and Participants</h3> Population-based cohort study using data of patients discharged alive after PCI for ACS from the Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease registry from April 1, 2012, to March 31, 2016, with follow-up to 1 year. Analysis began April 2018. <h3>Exposures</h3> Outpatient prescription for ticagrelor or clopidogrel within 31 days after PCI. Adherence was defined as a medication refill adherence value of 80% or higher. <h3>Main Outcomes and Measures</h3> Major adverse coronary events, a composite of all-cause death, hospitalization for ACS, unplanned coronary revascularization, or stent thrombosis within 365 days after index PCI. Secondary outcomes included hospitalization for major bleeding and emergency department visit for dyspnea. <h3>Results</h3> Of 11 185 individuals who underwent PCI, the median (interquartile range) age was 61 (54-71) years, and 2760 (24.7%) were women. Ticagrelor users (4076 [36.4%]) were generally younger and had fewer cardiac and noncardiac comorbidities than clopidogrel users. Ticagrelor was not associated with lower risk of MACE (adjusted hazard ratio [aHR], 0.97; 95% CI, 0.85-1.10); however, it was associated with an increased risk of major bleeding (aHR, 1.51; 95% CI, 1.29-1.78) and dyspnea (aHR, 1.98; 95% CI, 1.47-2.65). A total of 3328 ticagrelor users (81.6%) were adherent during the study vs 5256 of clopidogrel users (73.9%) (<i>P</i> &lt; .001; χ<sup>2</sup> = 86.4). In the full cohort, adherence was associated with a lower MACE risk (aHR, 0.79; 95% CI, 0.69-0.90 for adherence of ≥80% vs &lt;80%). Differences in other secondary outcomes were not statistically significant. Sensitivity and subgroup analyses were consistent with primary analyses. <h3>Conclusions and Relevance</h3> In this population-based cohort study of patients with ACS who underwent PCI, outpatient use of ticagrelor was not associated with a statistically significant reduction in MACE vs clopidogrel; however, it was associated with more major bleeding and dyspnea.
Early Clinical Experience of Trastuzumab Plus Capecitabine/Cisplatin (HXP) Therapy for Patients with Unresectable Advanced Gastric Cancer
Authors: H. Takeda, T. Tsumura, A. Sekikawa, E. Iguchi, T. Kanesaka, S. Saito, A. Nasu, H. Nishikawa, R. Kita, T. Maruo, Y. Okabe, Toru Kimura, Yukio Osaki, Tomoko Wakasa
Journal: Annals of Oncology (2012)
Glymphatic System Impairment in Alzheimer’s Disease and Idiopathic Normal Pressure Hydrocephalus
Authors: Benjamin C. Reeves, Jason K. Karimy, Adam J. Kundishora, Humberto Mestre, H. Mert Cerci, Charles Matouk, Seth L. Alper, Iben Lundgaard, Maiken Nedergaard, Kristopher T. Kahle
Journal: Trends in Molecular Medicine (2020)
Increased Tumor Penetration of Single-Domain Antibody–Drug Conjugates Improves <i>In Vivo</i> Efficacy in Prostate Cancer Models
Authors: Ian Nessler, Eshita Khera, Steven Vance, Anna Kopp, Qifeng Qiu, Thomas A. Keating, Adnan O. Abu-Yousif, Thomas Sandal, James Legg, Lorraine Thompson, Normann Goodwin, Greg M. Thurber
Journal: Cancer Research (2020)

Targeted delivery of chemotherapeutics aims to increase efficacy and lower toxicity by concentrating drugs at the site-of-action, a method embodied by the seven current FDA-approved antibody-drug conjugates (ADC). However, a variety of pharmacokinetic challenges result in relatively narrow therapeutic windows for these agents, hampering the development of new drugs. Here, we use a series of prostate-specific membrane antigen-binding single-domain (Humabody) ADC constructs to demonstrate that tissue penetration of protein-drug conjugates plays a major role in therapeutic efficacy. Counterintuitively, a construct with lower
Impact of Donor Source on Allogeneic Stem Cell Transplantation for Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia
Authors: S. Nishiwaki, K. Miyamura, K. Ohashi, M. Kurokawa, S. Taniguchi, T. Fukuda, K. Ikegame, H. Sakamaki, Y. Morishima, K. Kato, R. Suzuki, J. Tanaka
Journal: Annals of Oncology (2012)
Phase 3 Study (MONET1) of Motesanib Plus Carboplatin/Paclitaxel (C/P) in Patients with Advanced NSCLC: Asian Subgroup Analysis
Authors: K. Park, Y. Ichinose, G. Scagliotti, D. Spigel, J.H. Kim, T. Shinkai, K. Takeda, S.-W. Kim, T.-C. Hsia, R.K. Li, B. Tiangco, S. Yau, W.-T. Lim, B. Yao, Y.-j. Hei, K. Kubota
Journal: Annals of Oncology (2012)
Characteristics of Patients With HER2-Positive Metastatic (MBC) or Locally Advanced Breast Cancer (ABC), Treated With Trastuzumab (T) as 1st Line-Therapy and Progression-Free for at Least 3 Years: Interim Analysis of the Lorha Study
Authors: O. Tredan, B. You, P. Beuzeboc, D. Coeffic, A. Lortholary, M. Fellous, T. La Motte De Rouge, F. Andre, L. Arnould, J. Ferrero
Journal: Annals of Oncology (2012)
Concentric Tumor Shrinkage by Chemotherapy is a Good Prognostic Factor in Neoadjuvant Chemotherapy for Luminal Breast Cancer
Authors: I. Fukada, Y. Ito, S. Takahashi, C. Tsutsumi, T. Kobayashi, K. Kobayashi, Y. Nakayama, Y. Kawai, K. Hatake
Journal: Annals of Oncology (2012)
Phosphorylated Akt and MAPK expression in primary tumors and in corresponding metastases and clinical outcome in colorectal cancer patients receiving irinotecan-cetuximab.
Authors: Riccardo Giampieri, Mario Scartozzi, Elena Maccaroni, Alessandra Mandolesi, Simona Biagetti, Simona Alfonsi, Lucio Giustini, Cristian Loretelli, Luca Faloppi, Maristella Bianconi, Alessandro Bittoni, Michela Del Prete, Stefano Cascinu, Francesca Giorgi
Journal: Journal of Clinical Oncology (2012)

e14086 Background: Other than the well-known EGFR pathway activation via the Ras-Raf-MAP-kinase, a possible role of other potential biomarkers could be relevant in determining resistance to anti-EGFR treatment, such as the protein-serine/threonine kinase Akt. We tried to assess the role of Akt and MAPK expression in metastatic colorectal cancer patients and their relationship with outcome for patients receiving Irinotecan-Cetuximab. Methods: Eligible patients were metastatic colorectal cancer patients treated in 2 nd or 3 rd line setting with a irinotecan-cetuximab based regimen. Patients were tested for K-ras status and subsequently assessed by immunoistochemistry for pAkt and MAPK expression, both in primary tumours and metastases whenever sufficient tissue was available. The role of pAkt and MAPK expression was evaluated for K-ras wild type patients for different likelihood of response, overall survival and progression free survival. Response was evaluated by RECIST criteria. Survival analysis was performed via Kaplan-Meier method. Results: In metastases pAkt correlated with RR (9% vs. 58%, p=0.004), PFS (2.3 months vs.9.2 months p &lt; 0.0001) and OS (6.1 months vs.26.7 months p &lt; 0.0001) and pMAPK correlated with RR (10% vs, 47%, p = 0.002), PFS (2.3 months vs.8.6 months p &lt; 0.0001) and OS (7.8 months vs.26 months p=0.0004). At multivariate analysis pAkt and pMAPK in metastases were able to independently predict PFS. pAkt in metastases independently correlated with RR as well. Conclusions: pAkt and pMAPK expression in metastases may modulate the activity of EGFR-targeted antibodies. We could speculate that in patients with pAkt and pMAPK metastases expression targeting these factors may be crucial.
CNS Metastases, Subtypes and Survival in Breast Cancer: A Population Based Study in Eastern Switzerland
Authors: D. König, B. Thürlimann, F. Otto, L. Plasswilm, M. Hoefliger, I.K. Senn-Schönenberger, U. Müller, C. Öhlschlegel, H. Senn, S.M. Ess
Journal: Annals of Oncology (2012)
Left Ventricular Intramyocardial Fat Detected on Cardiac Computed Tomography in Patients With Stable Chest Pain
Authors: Júlia Karády, Thomas Mayrhofer, Borek Foldyna, Alexander Ivanov, Yasuka Kikuchi, Maros Ferencik, Michael T. Lu, Stefan B. Puchner, Hamed Emami, Nandini M. Meyersohn, Daniel O. Bittner, Pál Maurovich-Horvat, Pamela S. Douglas, Udo Hoffmann
Journal: JACC. Cardiovascular imaging (2020)
Homozygous Hypomorphic <i>HNF1A</i> Alleles Are a Novel Cause of Young-Onset Diabetes and Result in Sulfonylurea-Sensitive Diabetes
Authors: Shivani Misra, Neelam Hassanali, Amanda J. Bennett, Agata Juszczak, Richard Caswell, Kevin Colclough, Jonathan Valabhji, Sian Ellard, Nicholas S. Oliver, Anna L. Gloyn
Journal: Diabetes Care (2020)

OBJECTIVE Heterozygous loss-of-function mutations in HNF1A cause maturity-onset diabetes of the young (MODY). Affected individuals can be treated with low-dose sulfonylureas. Individuals with homozygous HNF1A mutations causing MODY have not been reported. RESEARCH DESIGN AND METHODS We phenotyped a kindred with young-onset diabetes and performed molecular genetic testing, a mixed meal tolerance test, a sulfonylurea challenge, and in vitro assays to assess variant protein function. RESULTS A homozygous HNF1A variant (p.A251T) was identified in three insulin-treated family members diagnosed with diabetes before 20 years of age. Those with the homozygous variant had low hs-CRP levels (0.2–0.8 mg/L), and those tested demonstrated sensitivity to sulfonylurea given at a low dose, completely transitioning off insulin. In silico modeling predicted a variant of unknown significance; however, in vitro studies supported a modest reduction in transactivation potential (79% of that for the wild type; P &amp;lt; 0.05) in the absence of endogenous HNF1A. CONCLUSIONS Homozygous hypomorphic HNF1A variants are a cause of HNF1A-MODY. We thus expand the allelic spectrum of variants in dominant genes causing diabetes.
Complement blockade for TA-TMA: lessons learned from large pediatric cohort treated with eculizumab
Authors: Sonata Jodele, Christopher E Dandoy, Adam Lane, Benjamin L Laskin, Ashley Teusink-Cross, Kasiani C Myers, Gregory H Wallace, Adam Nelson, Jack Bleesing, Ranjit S Chima, Russel Hirsch, Thomas D Ryan, Stefanie Woolridge Benoit, Kana Mizuno, Mikako Warren, Stella M Davies
Journal: Blood (2020)
Isolated Limb Perfusion in Locally-Advanced Limb Soft Tissue Sarcomas: Retrospective Study of A 23-Year Experience
Authors: M. Rastrelli, L.G. Campana, A. Vecchiato, P.L. Pilati, S. Valpione, R. Spina, C. Falci, A. Sommariva, A. Zanon, C.R. Rossi
Journal: Annals of Oncology (2012)
Brca Status, Molecular Profile and Clinical Variables in Primary Bilateral Breast Cancers: A Population-Based Cancer Registry Study
Authors: A. Musolino, M.A. Bella, M. Michiara, P. Zanelli, N. Naldi, B. Bortesi, P. Sgargi, R. Camisa, T.M. Neri, A. Ardizzoni
Journal: Annals of Oncology (2012)
High-Dose Etoposide as an Effective Mobilization Agent in NHL Previously Treated with CHOP ± RITUXIMAB
Authors: S.Y. Hyun, J. Jang, Y.D. Kim, D.Y. Whang, S.J. Kim, J.S. Kim, J.-W. Cheong, Y.H. Min
Journal: Annals of Oncology (2012)
Cost-Effectiveness and Quality-Adjusted Survival of Watch and Wait After Complete Response to Chemoradiotherapy for Rectal Cancer
Authors: Jacob A Miller, Hannah Wang, Daniel T Chang, Erqi L Pollom
Journal: JNCI Journal of the National Cancer Institute (2020)

Abstract Background Neoadjuvant chemoradiotherapy (CRT) followed by total mesorectal excision (TME) is the standard treatment for locally advanced rectal cancer. There is interest in deescalating local therapy after a clinical complete response to CRT. We hypothesized that a watch-and-wait (WW) strategy offers comparable cancer-specific survival, superior quality-adjusted survival, and reduced cost compared with upfront TME. Methods We developed a decision-analytic model to compare WW, low anterior resection, and abdominoperineal resection for patients achieving a clinical complete response to CRT. Rates of local regrowth, pelvic recurrence, and distant metastasis were derived from series comparing WW with TME after pathologic complete response. Lifetime incremental costs and quality-adjusted life-years (QALY) were calculated between strategies, and sensitivity analyses were performed to study model uncertainty. Results The base case 5-year cancer-specific survival was 93.5% (95% confidence interval [CI] = 91.5% to 94.9%) on a WW program compared with 95.9% (95% CI = 93.6% to 97.4%) after upfront TME. WW was dominant relative to low anterior resection, with cost savings of $28 500 (95% CI = $22 200 to $39 000) and incremental QALY of 0.527 (95% CI = 0.138 to 1.125). WW was also dominant relative to abdominoperineal resection, with a cost savings of $32 100 (95% CI = $21 800 to $49 200) and incremental QALY of 0.601 (95% CI = 0.213 to 1.208). WW remained dominant in sensitivity analysis unless the rate of surgical salvage fell to 73.0%. Conclusions Using current multi-institutional recurrence estimates, we observed comparable cancer-specific survival, superior quality-adjusted survival, and decreased costs with WW compared with upfront TME. Upfront TME was preferred when surgical salvage rates were low.
Pathological Complete Response to Trastuzumab Subcutaneous Fixed-Dose Formulation in the Hannah Study: Subgroup Analysis of Patient Demographics and Tumor Characteristics and Influence of Body Weight (BW) and Serum Trough Concentration (Ctrough) of Trastuzumab
Authors: B. Melichar, D. Stroyakovskiy, J.S. Ahn, M.V. Kopp, V. Srimuninnimit, G. Kunz, J. Li, T. van der Horst, S. Muehlbauer, C. Jackisch
Journal: Annals of Oncology (2012)
Analyzing changes in oncology trial records over time using automated semantic web-mining.
Authors: David J Cocker, Johanna Caroline Lievens, Kristof Geentjens, Piet Van Remortel, Mireille De Cre, Bart Naudts
Journal: Journal of Clinical Oncology (2012)

e13073 Background: Incorrect assumptions and poor feasibility are often cited as the major cause of study delay and outcome resolution. Trial placement and recruitment can be optimized by monitoring and regular assessment of trial registries. However, just a snapshot analysis does not take into account retrospective editing of records. This paper evaluates the effectiveness of a robotic, semantic analysis of registered oncology trials to assess individual changes in trial records over time. Methods: Evaluating individual trial records from 2008 to 2012 with state-of-the art natural language processing and semantic linking of data fields within clinical trial registries and literature databases to add increased resolution to erroneous or inadequate registry fields. Results: Substantial modifications are made to registration records over the life cycle of a clinical trial. Quantifiable fields as recruitment, site numbers and end dates all deviate significantly from the study roll-out. Analysis of oncology trials recruiting over 200 patients between 2008 and 2012 shows two thirds of trials deviate from the initial record. Most frequently study end date is delayed (about 50% of all trials) or enrollment targets are amended (at least 25%). Over all oncology indications, enrollment increases are twice more frequent as decreases. However, there are notable exceptions such as lung cancer, where enrollment is frequently decreased. A differential analysis of countries and sites in commercial oncology phase III trials over the period revealed a marked shift of research to sites in France, Spain, the UK and China. However, when sites were added to ongoing trials this general trend was not entirely followed as Poland, Japan, Belgium, Argentina and Switzerland were frequently chosen as additional countries above the normal distribution, suggesting these are preferred countries for trial “rescue”. Conclusions: This paper demonstrates the effectiveness of automated semantic web-mining to identify incorrect clinical trial assumptions and subsequent remediation.
miR-149 Suppresses Breast Cancer Metastasis by Blocking Paracrine Interactions with Macrophages
Authors: Ismael Sánchez-González, Anja Bobien, Christian Molnar, Simone Schmid, Michaela Strotbek, Melanie Boerries, Hauke Busch, Monilola A. Olayioye
Journal: Cancer Research (2020)

Paracrine activation of cells contained in the tumor microenvironment promotes tumor progression and metastasis. In breast cancer, malignant cells recruit and educate macrophages into a M2 tumor-promoting phenotype that supports the metastatic spread of cancer cells. Here, we show that miR-149 functions as a metastasis-suppressing microRNA in breast cancer cells by limiting colony-stimulating factor-1 (CSF1)-dependent recruitment and M2 polarization of macrophages. In lymph node-positive, triple-negative breast cancer (TNBC) tissues, low miR-149 expression correlated with macrophage infiltration and reduced patient survival. By directly targeting CSF1, miR-149 expression in TNBC cell lines (MDA-MB-231 and BT-549) inhibited the recruitment of human monocytic THP-1 cells and primary human macrophages. Furthermore, in macrophages cocultured with MDA-MB-231 cells expressing miR-149, epidermal growth factor (EGF) and amphiregulin expression levels were strongly reduced, resulting in reduced EGF receptor activation in the cancer cells. In vivo, lung metastases developing from orthotopic MDA-MB-231 tumors were reduced by 75% by miR-149 expression, and this was associated with impaired M2 macrophage infiltration of the primary tumors. These data suggest that miR-149 downregulation functionally contributes to breast tumor progression by recruiting macrophages to the tumor and facilitating CSF1 and EGF receptor cross-talk between cancer cells and macrophages. SIGNIFICANCE: These findings contribute to the understanding of tumor-stroma interactions by showing that miR-149 downregulation in TNBC enhances reciprocal growth factor signaling between macrophages and cancer cells, which promotes tumor progression and metastasis. GRAPHICAL ABSTRACT: http://cancerres.aacrjournals.org/content/canres/80/6/1330/F1.large.jpg.
A Ugt1a1*28 and *6 Genotype-Directed Phase I Study of Irinotecan Plus Infusional Leucovorin and 5-Fluorouracil (sLV5FU2) in Patients with Previously Untreated Metastatic Colorectal Cancer (MCRC)
Authors: K.-P. Kim, Y.S. Hong, J.-L. Lee, K.S. Bae, H.-S. Kim, J.-G. Shin, J.S. Lee, T.W. Kim
Journal: Annals of Oncology (2012)
Assigning values to the Localized Scleroderma Cutaneous Assessment Tool (LoSCAT) score indicating degree of severity and responsiveness: fostering practical use in clinic and therapeutic studies for morphoea/localized scleroderma
Authors: K.S. Torok
Journal: British Journal of Dermatology (2020)

Linked Article:Teske and Jacobe. Br J Dermatol 2020; 182:398–404.
How Should we Manage the Central Vein Access Port System in Outpatient Cancer Chemotherapy when the Port System Can be Flushed, but no Blood Aspirated?
Authors: H. Nishimori, H. Nishimoto, N. Kouge, Y. Tsuyumu, S. Matsushima, M. Kuyama, M. Fukutake, Y. Inoue, M. Fujita, K. Hotta, M. Tabata
Journal: Annals of Oncology (2012)
Detection of Circulating Tumour Cells in Peripheral Blood of Patients With Malignant Pleural Mesothelioma
Authors: J. Raphael, C. Massard, F. Farace, G. Le Teuff, J. Margery, F. Billiot, B. Besse, A. Hollebecque, J. Soria, D. Planchard
Journal: Annals of Oncology (2012)
It’s my safe space: The life-saving role of the internet in the lives of transgender and gender diverse youth
Authors: Ashley Austin, Shelley L. Craig, Nicole Navega, Lauren B. McInroy
Journal: International Journal of Transgender Health (2020)

Background: Public awareness of Transgender and Gender Diverse (TGD) identities has grown significantly; however, acceptance and support remain elusive for many TGD youth. Resultant experiences of marginalization and stigmatization contribute to elevated rates of psychological distress and suicidality among TGD youth. Emergent evidence suggests that the internet may offer TGD youth safety, support, and community previously unavailable.Aim: The primary aim of this qualitative inquiry is to engage in an in-depth exploration of the online experiences and processes which help protect against psychological distress and promote well-being among TGD youth.Methods: Data were culled from a mixed-methods, online study of sexual and gender minority youth from across the United States and Canada which followed Institutional Review Board approved protocols. Participants for this study represent a sample (n = 260) of TGD participants aged 14–22 (x̄ = 17.30). Data were analyzed using Charmaz' grounded theory strategies.Results: Data revealed that the internet offers TGD youth affirming spaces that, for the most part, do not exist in their offline lives. Online, TGD youth were able to engage meaningfully with others as their authentic selves, often for the first time. These experiences fostered well-being, healing, and growth through five processes: 1. Finding an escape from stigma and violence, 2. Experiencing belonging, 3. Building confidence, 4. Feeling hope, and 5. Giving back.Discussion: The unique and innovative ways in which participants use online spaces to foster resilience offer important insights to inform affirmative practices with TGD young people.
First-In-Human Phase I Administration of YS110, A Humanized Monoclonal Antibody Directed Against the CD26 Molecule in Cancer Patients
Authors: E. Angevin, V. Trillet-Lenoir, N. Isambert, J. Alexandre, F. Valleix, T. Podoll, I. Miyashita, T. Yamada, Y. Kaneko, C. Morimoto
Journal: Annals of Oncology (2012)
HER2 Status in Oesophagogastric Junction and Gastric Cancer - the Irish Landscape
Authors: A. Jayaram, J.E. Battley, M.Y. Teo, R. Abdul Rahman, R. Bambury, M.W. Bennett, M. Margaret Sheehan, R. McDermott, D.G. Power, G. Leonard
Journal: Annals of Oncology (2012)
Results of Hrqol Data from Palette: A Randomized Double Blind Phase III Trial of Pazopanib Versus Placebo in Metastatic Soft Tissue Sarcoma (STS) Patients. An Eortc Stbsg Global Network Study (EORTC 62072)
Authors: C. Coens, W.T.A. van der Graaf, J. Blay, S.P. Chawla, D. Kim, R. Sanfilippo, S. Manson, M. Ouali, S. Marreaud, A. Bottomley
Journal: Annals of Oncology (2012)
Updating the dual systems model of temporal cognition: Reasoning with dynamic systems theory
Authors: Annette Hohenberger
Journal: Behavioral and Brain Sciences (2019)

Abstract This commentary construes the relation between the two systems of temporal updating and temporal reasoning as a bifurcation and tracks it across three time scales: phylogeny, ontogeny, and microgeny. In taking a dynamic systems approach, flexibility, as mentioned by Hoerl &amp; McCormack, is revealed as the key characteristic of human temporal cognition.
Phase II Study of Combination Therapy with S-1 and Cetuximab in Patients with Kras Wild-Type Unresectable Colorectal Cancer, who Had Previously Received Irinotecan, Oxaliplatin, and Fluoropyrimidines (KSCC0901)
Authors: M. Kitazono, K. Kobayashi, Y. Emi, Y. Kakechi, T. Takahashi, Y. Akagi, A. Tuji, K. Yoshida, H. Baba, H. Ogata, M. Shimokawa, S. Natsugoe, Y. Maehara
Journal: Annals of Oncology (2012)
Proteomic Predictors of Outcome After Adjuvant Anti-Hormonal Therapy for Hormone Receptor-Positive Breast Cancer
Authors: B. Hennessy, D. Faratian, Z. Ju, A. Lluch-Hernandez, S. Myhre, A.M. Gonzalez-Angulo, J. Overgaard, J. Alsner, A. Borresen-Dale, G.B. Mills
Journal: Annals of Oncology (2012)
Self-calibrated brain network estimation and joint non-convex multi-task learning for identification of early Alzheimer's disease
Authors: Baiying Lei, Nina Cheng, Alejandro F Frangi, Ee-Leng Tan, Jiuwen Cao, Peng Yang, Ahmed Elazab, Jie Du, Yanwu Xu, Tianfu Wang
Journal: Medical Image Analysis (2020)